Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
July 30, 2015 9:28 AM EDT
Janney Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Neutral.
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
...
More
July 30, 2015 6:46 AM EDT
RBC Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Sector Perform with a price target of $32.00 (from $26.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
...
More
July 29, 2015 4:05 PM EDT
Depomed (NASDAQ: DEPO) announced that its Board of Directors, after careful consideration and with the assistance of its independent financial and legal advisors, has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon") to acquire all of the outstanding shares of Depomed in an all-stock transaction (the "July 21 Proposal").
The Depomed Board concluded that the July 21 Proposal is inadequate and not in the best interests of Depomed and its shareholders. The Depomed Board believes that the... More
